AB Science S.A (PA:AB) — Market Cap & Net Worth
Market Cap & Net Worth: AB Science S.A (AB)
AB Science S.A (PA:AB) has a market capitalization of $81.71 Million (€69.89 Million) as of May 2, 2026. Listed on the PA stock exchange, this France-based company holds position #19963 globally and #310 in its home market, demonstrating a -9.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AB Science S.A's stock price €1.06 by its total outstanding shares 66184793 (66.18 Million). Analyse cash efficiency ratio of AB Science S.A to see how efficiently the company converts income to cash.
AB Science S.A Market Cap History: 2015 to 2026
AB Science S.A's market capitalization history from 2015 to 2026. Data shows change from $946.32 Million to $81.71 Million (-20.68% CAGR).
AB Science S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AB Science S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
63.66x
AB Science S.A's market cap is 63.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $946.32 Million | $2.28 Million | -$26.72 Million | 414.33x | N/A |
| 2016 | $1.06 Billion | $1.51 Million | -$27.70 Million | 701.93x | N/A |
| 2017 | $645.32 Million | $1.74 Million | -$27.12 Million | 371.09x | N/A |
| 2018 | $268.34 Million | $1.70 Million | -$26.06 Million | 157.76x | N/A |
| 2019 | $416.29 Million | $1.57 Million | -$21.75 Million | 264.98x | N/A |
| 2020 | $1.52 Billion | $1.58 Million | -$15.04 Million | 960.98x | N/A |
| 2021 | $928.52 Million | $1.61 Million | -$14.46 Million | 577.80x | N/A |
| 2022 | $548.60 Million | $958.00K | -$13.62 Million | 572.65x | N/A |
| 2023 | $275.08 Million | $970.00K | -$10.05 Million | 283.58x | N/A |
| 2024 | $68.25 Million | $1.07 Million | -$7.83 Million | 63.66x | N/A |
Competitor Companies of AB by Market Capitalization
Companies near AB Science S.A in the global market cap rankings as of May 2, 2026.
Key companies related to AB Science S.A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
AB Science S.A Historical Marketcap From 2015 to 2026
Between 2015 and today, AB Science S.A's market cap moved from $946.32 Million to $ 81.71 Million, with a yearly change of -20.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €81.71 Million | -31.25% |
| 2025 | €118.85 Million | +74.15% |
| 2024 | €68.25 Million | -75.19% |
| 2023 | €275.08 Million | -49.86% |
| 2022 | €548.60 Million | -40.92% |
| 2021 | €928.52 Million | -38.96% |
| 2020 | €1.52 Billion | +265.43% |
| 2019 | €416.29 Million | +55.13% |
| 2018 | €268.34 Million | -58.42% |
| 2017 | €645.32 Million | -39.04% |
| 2016 | €1.06 Billion | +11.86% |
| 2015 | €946.32 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of AB Science S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $81.71 Million USD |
| MoneyControl | $81.71 Million USD |
| MarketWatch | $81.71 Million USD |
| marketcap.company | $81.71 Million USD |
| Reuters | $81.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more